2023
DOI: 10.1158/1538-7755.disp22-b086
|View full text |Cite
|
Sign up to set email alerts
|

Abstract B086: Barriers to use of adjuvant endocrine therapy among Black women with breast cancer: A qualitative investigation

Abstract: Post-operative or adjuvant endocrine therapy (AET) is the mainstay of treatment for hormone receptor-positive (HR+) breast cancer. When taken daily for 5-to-10 years, AET improves the time to disease recurrence and overall survival rates. However, past work has shown that Black women are less likely to begin prescribed AET treatments and less likely to take these medications as directed, often discontinuing treatment early. For hormone receptor-positive (HR+) breast cancer, rates of death from breast cancer ar… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles